Us preventive services task force colon cancer screening

Practice Guideline

. 2021 May 18;325(19):1965-1977.

doi: 10.1001/jama.2021.6238.

Karina W Davidson  1 Michael J Barry  2 Carol M Mangione  3 Michael Cabana  4 Aaron B Caughey  5 Esa M Davis  6 Katrina E Donahue  7 Chyke A Doubeni  8 Alex H Krist  9   10 Martha Kubik  11 Li Li  12 Gbenga Ogedegbe  13 Douglas K Owens  14 Lori Pbert  15 Michael Silverstein  16 James Stevermer  17 Chien-Wen Tseng  18   19 John B Wong  20

Affiliations

  • PMID: 34003218
  • DOI: 10.1001/jama.2021.6238

Practice Guideline

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force et al. JAMA. 2021.

Erratum in

  • Incorrect Axis Labels in Figures.

    [No authors listed] [No authors listed] JAMA. 2021 Aug 24;326(8):773. doi: 10.1001/jama.2021.12404. JAMA. 2021. PMID: 34427621 Free PMC article. No abstract available.

Abstract

Importance: Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening.

Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies.

Population: Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).

Evidence assessment: The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit.

Recommendation: The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).

Comment in

  • US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty.

    Ng K, May FP, Schrag D. Ng K, et al. JAMA. 2021 May 18;325(19):1943-1945. doi: 10.1001/jama.2021.4133. JAMA. 2021. PMID: 34003238 No abstract available.

  • Colorectal Cancer Screening Starting at Age 45 Years-Ensuring Benefits Are Realized by All.

    Mehta SJ, Morris AM, Kupfer SS. Mehta SJ, et al. JAMA Netw Open. 2021 May 3;4(5):e2112593. doi: 10.1001/jamanetworkopen.2021.12593. JAMA Netw Open. 2021. PMID: 34003278 Free PMC article. No abstract available.

  • Striving to optimize colorectal cancer prevention.

    Brenner H, Hoffmeister M. Brenner H, et al. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):677-678. doi: 10.1038/s41575-021-00494-6. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34282305 No abstract available.

  • US Preventive Services Task Force Recommendation Statement on Screening for Colorectal Cancer.

    Haghighat S, Sussman DA, Deshpande A. Haghighat S, et al. JAMA. 2021 Oct 5;326(13):1328. doi: 10.1001/jama.2021.13466. JAMA. 2021. PMID: 34609459 No abstract available.

Summary for patients in

  • Screening for Colorectal Cancer.

    Jin J. Jin J. JAMA. 2021 May 18;325(19):2026. doi: 10.1001/jama.2021.6557. JAMA. 2021. PMID: 34003224 No abstract available.

Similar articles

  • Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

    US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. US Preventive Services Task Force, et al. JAMA. 2016 Jun 21;315(23):2564-2575. doi: 10.1001/jama.2016.5989. JAMA. 2016. PMID: 27304597

  • Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

    US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng CW. US Preventive Services Task Force, et al. JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710. JAMA. 2018. PMID: 29801017

  • Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force.

    Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, Perdue LA, Lin JS, Siegel RL, Doria-Rose VP, Feuer EJ, Zauber AG, Kuntz KM, Lansdorp-Vogelaar I. Knudsen AB, et al. JAMA. 2021 May 18;325(19):1998-2011. doi: 10.1001/jama.2021.5746. JAMA. 2021. PMID: 34003219 Free PMC article.

  • Suicidal Ideation.

    Harmer B, Lee S, Duong TVH, Saadabadi A. Harmer B, et al. 2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 33351435 Free Books & Documents.

  • Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

    US Preventive Services Task Force, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. US Preventive Services Task Force, et al. JAMA. 2022 Aug 23;328(8):746-753. doi: 10.1001/jama.2022.13044. JAMA. 2022. PMID: 35997723 Review.

Cited by

  • Feasibility of Rescue Colonoscopy Using a Short-type Enteroscope (SIF-H290S) without Overtube after Incomplete Colonoscopy: A Single-center Retrospective Pilot Study.

    Ochiai Y, Odagiri H, Hayasaka J, Okamura T, Suzuki Y, Mitsunaga Y, Fuchinoue K, Tanaka M, Nomura K, Yamashita S, Matsui A, Kikuchi D, Hoteya S. Ochiai Y, et al. J Anus Rectum Colon. 2022 Oct 27;6(4):282-288. doi: 10.23922/jarc.2022-005. eCollection 2022. J Anus Rectum Colon. 2022. PMID: 36348946 Free PMC article.

  • The Potential Role of Artificial Intelligence in Lung Cancer Screening Using Low-Dose Computed Tomography.

    Grenier PA, Brun AL, Mellot F. Grenier PA, et al. Diagnostics (Basel). 2022 Oct 8;12(10):2435. doi: 10.3390/diagnostics12102435. Diagnostics (Basel). 2022. PMID: 36292124 Free PMC article. Review.

  • Single CT Appointment for Double Lung and Colorectal Cancer Screening: Is the Time Ripe?

    Mascalchi M, Picozzi G, Puliti D, Gorini G, Mantellini P, Sali L. Mascalchi M, et al. Diagnostics (Basel). 2022 Sep 27;12(10):2326. doi: 10.3390/diagnostics12102326. Diagnostics (Basel). 2022. PMID: 36292015 Free PMC article. Review.

  • The First Year of the COVID-19 Pandemic: Changes in Preventive Services in Community Health Centers.

    Star J, Han X, Makaroff LA, Minihan AK, Jemal A, Bandi P. Star J, et al. Am J Prev Med. 2022 Oct 20:S0749-3797(22)00462-7. doi: 10.1016/j.amepre.2022.08.023. Online ahead of print. Am J Prev Med. 2022. PMID: 36273931 Free PMC article.

  • Early onset colorectal cancer: Challenges across the cancer care continuum.

    AlZaabi A, AlHarrasi A, AlMusalami A, AlMahyijari N, Al Hinai K, ALAdawi H, Al-Shamsi HO. AlZaabi A, et al. Ann Med Surg (Lond). 2022 Aug 22;82:104453. doi: 10.1016/j.amsu.2022.104453. eCollection 2022 Oct. Ann Med Surg (Lond). 2022. PMID: 36268309 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

  • Full Text Sources

    • Ovid Technologies, Inc.
    • Silverchair Information Systems
  • Other Literature Sources

    • scite Smart Citations
  • Medical

    • Genetic Alliance
    • MedlinePlus Health Information

What is the US preventive Services Task Forces recommendation for colorectal cancer screening?

Screening Recommendations Regular screening, beginning at age 45, is the key to preventing colorectal cancer and finding it early. The U.S. Preventive Services Task Force (Task Force) recommends that adults age 45 to 75 be screened for colorectal cancer.

When should I start colonoscopy screening USPSTF?

The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history.

How often should you get screened for colon cancer?

The doctor checks for polyps or cancer inside the rectum and lower third of the colon. How often: Every 5 years, or every 10 years with a FIT every year.
Cologuard is not recommended for higher-risk patients that have had colon cancer, have a family history, have inflammatory bowel disorders like Crohn's disease or have had a personal history of colon polyps.